Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Tuesday, October 12, 2010 at 5:57 PM

Comments (0)     E-mail E-mail article      Print Print      Share Share

Bristol-Myers closes ZymoGenetics buyout

Bristol-Myers Squibb said Tuesday it finished buying out drugmaker ZymoGenetics by means of a "short-form merger. " In that process, all...

NEW YORK — Bristol-Myers Squibb said Tuesday it finished buying out drugmaker ZymoGenetics by means of a "short-form merger."

In that process, all of ZymoGenetics' outstanding common shares were converted into the right to receive $9.75 in cash without interest, less any required withholding taxes.

Bristol-Myers said Friday, after shareholders of ZymoGenetics tendered about 95 percent of their stock in favor of the deal, that it would soon complete the buyout.

On Sept. 10, Bristol-Myers said it would buy ZymoGenetics for $735 million excluding cash on hand. That equaled a price of $9.75 a share, or 77 percent more than ZymoGenetics' closing price of $5.51 before the initial announcement.

Seattle's ZymoGenetics makes Recothrom, a drug used to reduce bleeding during surgeries.

E-mail E-mail article      Print Print      Share Share

More Business & Technology

UPDATE - 09:46 AM
Exxon Mobil wins ruling in Alaska oil spill case

UPDATE - 09:32 AM
Bank stocks push indexes higher; oil prices dip

UPDATE - 08:04 AM
Ford CEO Mulally gets $56.5M in stock award

UPDATE - 07:54 AM
Underwater mortgages rise as home prices fall

NEW - 09:43 AM
Warner Bros. to offer movie rentals on Facebook

More Business & Technology headlines...

Comments
No comments have been posted to this article.

advertising


Get home delivery today!

Video

Advertising

AP Video

Entertainment | Top Video | World | Offbeat Video | Sci-Tech

Marketplace

 
Most read
Most commented
Most e-mailed
 
 

Most viewed imagesMore

Advertising